These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 8102845

  • 1. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
    Morgenstern H, Glazer WM.
    Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
    [Abstract] [Full Text] [Related]

  • 2. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
    Glazer WM, Morgenstern H, Doucette JT.
    J Clin Psychiatry; 1993 Apr; 54(4):133-9. PubMed ID: 8098030
    [Abstract] [Full Text] [Related]

  • 3. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
    Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM.
    J Clin Psychiatry; 2010 Apr; 71(4):463-74. PubMed ID: 20156410
    [Abstract] [Full Text] [Related]

  • 4. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.
    Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, Bailey A, Fell RL, McAdams LA.
    Arch Gen Psychiatry; 1995 Sep; 52(9):756-65. PubMed ID: 7654127
    [Abstract] [Full Text] [Related]

  • 5. Handedness and the risk of tardive dyskinesia.
    Morgenstern H, Glazer WM, Doucette JT.
    Biol Psychiatry; 1996 Jul 01; 40(1):35-42. PubMed ID: 8780853
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ, Soares KV.
    Cochrane Database Syst Rev; 2000 Jul 01; (2):CD000459. PubMed ID: 10796546
    [Abstract] [Full Text] [Related]

  • 12. Tardive dyskinesia in the aged. Duration of treatment relationships.
    Toenniessen LM, Casey DE, McFarland BH.
    Arch Gen Psychiatry; 1985 Mar 01; 42(3):278-84. PubMed ID: 2858189
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tardive dyskinesia: managing a common neuroleptic side effect.
    Jeste DV, Krull AJ, Kilbourn K.
    Geriatrics; 1990 Dec 01; 45(12):49-54. PubMed ID: 1979304
    [Abstract] [Full Text] [Related]

  • 15. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center.
    Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK.
    J Clin Psychopharmacol; 2004 Dec 01; 24(6):592-8. PubMed ID: 15538119
    [Abstract] [Full Text] [Related]

  • 16. Ten-year outcome of tardive dyskinesia.
    Gardos G, Casey DE, Cole JO, Perenyi A, Kocsis E, Arato M, Samson JA, Conley C.
    Am J Psychiatry; 1994 Jun 01; 151(6):836-41. PubMed ID: 7910437
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.